Compare Flowserve Corporation Common Stock (FLS) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flowserve Corporation Common Stock vs Globus Medical Inc. Class A Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $69.78 (market cap $9.08B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Flowserve Corporation Common Stock and Globus Medical Inc. Class A Common Stock are close in size by market cap, and Flowserve Corporation Common Stock pays a 1.23% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 6 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FLS | GMED | |
|---|---|---|
Market Cap | $9.08B | $10.25B |
Volume | 1,742,251 | 1,108,124 |
Sector | Industrials | Health |
52-Week High | $92.04 | $96.82 |
52-Week Low | $50.41 | $58.33 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.67B | $9.76B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flowserve Corporation Common Stock
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
